Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allos Oncologic Efaproxiral “Approvable” Pending Phase III ENRICH Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA followed the recommendations of its Oncology Drugs Advisory Committee in issuing an “approvable” letter. Efaproxiral approval is also conditional on FDA clearance of Allos’ manufacturing facility and forthcoming agency comments on pharmacology, toxicology and chemistry issues.

You may also be interested in...



Allos Drops Oncologic Efaproxyn After Failed Phase III Study

Firm will advance chemotherapeutic pipeline that includes Phase II lymphoma treatment PDX.

Allos Drops Oncologic Efaproxyn After Failed Phase III Study

Firm will advance chemotherapeutic pipeline that includes Phase II lymphoma treatment PDX.

Schering-Plough's Temodar Gets Priority Review For First-Line Glioma

The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel